STRYKER CORP（SYK）の決算・業績分析
STRYKER CORPの2025年有価証券報告書をAI分析。売上高$25.1B(+11.2%)。営業利益$4.9B。Health Care。
目次
STRYKER CORPの2025年度 業績サマリー
STRYKER CORP（証券コード: SYK）の2025年度決算・業績分析。売上高は$25.1B（前年比+11.2%）。営業利益は$4.9B（前年比+32.5%）。純利益は$3.2B（前年比+8.5%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
STRYKER CORPの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 7.8% YoY to $18.4B (XBRL), driven by strong performance across MedSurg, Neurotechnology, and Orthopaedics segments.
- Net income surged 18.3% YoY to $2.4B (XBRL), with net margin expanding to 12.8% (XBRL), reflecting improved cost management and operational efficiency.
- Free cash flow (FCF) reached $2.0B (XBRL), up from $2.6B operating cash flow (OCF) (XBRL) after $588M in capital expenditures (CapEx) (XBRL).
- Equity ratio improved to 41.6% (XBRL), while net debt/EBITDA stood at 1.9x (XBRL), indicating a balanced capital structure.
STRYKER CORPの売上高変化の要因
- •Revenue grew 7.8% YoY to $18.4B (XBRL), with a 5-year CAGR of 8.5% (XBRL). Historical data shows steady growth from $13.6B in FY2020 to $18.4B in FY2024 (XBRL). Operating income increased 9.9% YoY to $2.8B (XBRL), while net income rose 18.3% YoY to $2.4B (XBRL). The MedSurg and Neurotechnology segments, along with Orthopaedics, drove growth through product innovation and market expansion.
STRYKER CORPの営業利益変化の要因
- •Gross margin improved to 62.8% (XBRL), operating margin to 15.4% (XBRL), and net margin to 12.8% (XBRL). EBITDA reached $4.1B (22.3% of revenue) (XBRL). Operating income grew 9.9% YoY (XBRL), outpacing revenue growth, reflecting cost discipline. Net income surged 18.3% YoY (XBRL), aided by efficient R&D spending ($1.5B) (XBRL) and strong pricing power.
STRYKER CORPの事業リスクと対応
Weakening economic conditions could reduce demand for medical products (10-K).
Geopolitical risks, such as international conflicts, may increase market volatility (10-K).
Pricing pressures and cost-containment measures could harm product demand (10-K).
Foreign currency exchange fluctuations may impact financial results (10-K).
Legislative/regulatory changes, including healthcare reforms, pose compliance and operational risks (10-K).
Competitive pressures and challenges in integrating acquisitions (e.g., Inari) may affect growth (10-K).
STRYKER CORPの事業内容
Stryker Corp (SYK) is a global leader in medical technologies, generating revenue through the sale of innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that improve healthcare outcomes (10-K). Key products include surgical equipment, implants, endoscopic systems, and AI-assisted virtual care platforms (10-K). The company serves doctors, hospitals, and healthcare facilities with no significant customer concentration (10-K). Competitors include Zimmer Biomet, Medtronic, Johnson & Johnson MedTech, and others (10-K). Stryker's competitive advantages include a broad product portfolio and innovation in technologies like SurgiCount+ AI (10-K).
STRYKER CORPのAI業績分析レポート（2024年度）
```markdown
Stryker Corp (SYK) Annual Report Analysis FY2024
Highlights
Business Overview
Stryker Corp (SYK) is a global leader in medical technologies, generating revenue through the sale of innovative products and services in MedSurg, Neurotechnology, and Orthopaedics. Key products include surgical equipment, implants, endoscopic systems, and AI-assisted virtual care platforms. The company serves doctors, hospitals, and healthcare facilities with no significant customer concentration. Competitors include Zimmer Biomet, Medtronic, Johnson & Johnson MedTech, and others. Stryker's competitive advantages include a broad product portfolio and innovation in technologies like SurgiCount+ AI.
Revenue Analysis
Revenue grew 7.8% YoY to $18.4B (XBRL), with a 5-year CAGR of 8.5% (XBRL). Historical data shows steady growth from $13.6B in FY2020 to $18.4B in FY2024 (XBRL). Operating income increased 9.9% YoY to $2.8B (XBRL), while net income rose 18.3% YoY to $2.4B (XBRL). The MedSurg and Neurotechnology segments, along with Orthopaedics, drove growth through product innovation and market expansion.
Profitability Analysis
Gross margin improved to 62.8% (XBRL), operating margin to 15.4% (XBRL), and net margin to 12.8% (XBRL). EBITDA reached $4.1B (22.3% of revenue) (XBRL). Operating income grew 9.9% YoY (XBRL), outpacing revenue growth, reflecting cost discipline. Net income surged 18.3% YoY (XBRL), aided by efficient R&D spending ($1.5B) (XBRL) and strong pricing power.
Balance Sheet Analysis
Equity ratio improved to 41.6% (XBRL), with total equity rising to $16.6B (XBRL). Long-term debt totaled $10.9B (XBRL), resulting in a net debt/EBITDA ratio of 1.9x (XBRL). Current ratio was 1.58x (XBRL), indicating strong liquidity. Cash reserves stood at $3.0B (XBRL), supporting growth initiatives and shareholder returns.
Cash Flow Analysis
Operating cash flow (OCF) was $2.6B (XBRL), with FCF of $2.0B (XBRL) after $588M in CapEx (XBRL). Dividends paid reached $1.1B (XBRL), reflecting a payout ratio of 44.6% (XBRL). Capital expenditures were $588M (XBRL), or 3.2% of revenue (XBRL), with CapEx/D&A ratio at 0.46x (XBRL).
Working Capital Analysis
Receivables days were 74 days (XBRL), inventory days were 257 days (XBRL), and asset turnover was 0.46x (XBRL). No data on payables days or cash conversion cycle (CCC) was provided (N/A).
Risks
Outlook
N/A. The 10-K does not provide explicit management guidance or forward-looking trends in the provided data (N/A).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 13.6B | 14.9B | 14.4B | 17.1B | 18.4B | 20.5B |
| Operating Income | 2.5B | 2.7B | 2.2B | 2.6B | 2.8B | 3.9B |
| Net Income | 3.6B | 2.1B | 1.6B | 2.0B | 2.4B | 3.2B |
| Total Assets | 27.2B | 30.2B | 34.3B | 36.9B | 39.9B | 43.0B |
| Total Equity | 11.7B | 12.8B | 13.1B | 14.9B | 16.6B | 18.6B |
| Operating Cash Flow | 2.6B | 2.2B | 3.3B | 3.3B | 2.6B | 3.7B |
```
Health Careの企業一覧
STRYKER CORPと同じ「Health Care」セクターの企業